Amelioration of Clostridium difficile infection in mice by dietary supplementation with indole-3-carbinol

Annals of Surgery

Volumn 265, Issue 6, 2017, Pages 1183-1191

  Julliard, Walker ^a   De Wolfe, Travis J ^b   Fechner, John H ^a   Safdar, Nasia ^a   Agni, Rashmi ^a   Mezrich, Joshua D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Aryl Hydrocarbon receptor; Clostridium difficile; Dietary supplement

Indexed keywords

3 INDOLEMETHANOL; AROMATIC HYDROCARBON RECEPTOR; BETA ACTIN; CIPROFLOXACIN; CLINDAMYCIN; CYTOCHROME P450 1A1; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; ANTIINFECTIVE AGENT; INDOLE DERIVATIVE; INDOLE-3-CARBINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL TRANSLOCATION; CD4+ T LYMPHOCYTE; CECUM; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY SUPPLEMENT; DISEASE SEVERITY; DRUG EFFICACY; FECES MICROFLORA; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; IMMUNOCOMPETENT CELL; INFECTION PREVENTION; INFLAMMATION; LYMPHOID CELL; MALE; MORBIDITY; MORTALITY; MOUSE; MUCOSAL IMMUNITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THERAPY EFFECT; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; CLOSTRIDIUM INFECTIONS; DISEASE MODEL; IMMUNOLOGY; LEUKOCYTE ACTIVATION; PEPTOCLOSTRIDIUM DIFFICILE; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TRANSLOCATION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; IMMUNITY, MUCOSAL; INDOLES; MALE; MICE, INBRED C57BL; NEUTROPHIL ACTIVATION; RECEPTORS, ARYL HYDROCARBON; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84973544458     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001830     Document Type: Article

References (38)

1. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: A systematic review. JAMA. 2015;313:398-408.
2. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146:1547-1553.
3. Surawicz CM. Clostridium difficile infection: risk factors, diagnosis, and management. Curr Treat Options Gastroenterol. 2015;13:121-129.
4. Regnault H, Bourrier A, Lalande V, et al. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: A retrospective assessment. Dig Liver Dis. 2014;46:1086-1092.
5. Biswal S. Proton pump inhibitors and risk for Clostridium difficile associated diarrhea. Biomed J. 2014;37:178-183.
6. Lessa FC, Winston LG, McDonald LC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:2369-2370.
7. Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med. 2016;(1):56-61.
8. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772-1778.
9. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebocontrolled, multicentre trial. Lancet. 2013;382:1249-1257.
10. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415.
11. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114.
12. Geiger TL, Abt MC, Gasteiger G, et al. Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J Exp Med. 2014;211:1723-1731.
13. Hasegawa M, Yada S, Liu MZ, et al. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity. 2014;41:620-632.
14. Kiss EA, Vonarbourg C, Kopfmann S, et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science. 2011;334:1561-1565.
15. Li Y, Innocentin S, Withers DR, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011;147:629-640.
16. Basu R, O'Quinn DB, Silberger DJ, et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity. 2012;37:1061-1075.
17. Ahlfors H, Morrison PJ, Duarte JH, et al. IL-22 fate reporter reveals origin and control of IL-22 production in homeostasis and infection. J Immunol. 2014;193:4602-4613.
18. Martin B, Hirota K, Cua DJ, et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity. 2009;31:321-330.
19. Qiu J, Heller JJ, Guo X, et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92-104.
20. Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39:372-385.
21. Chen X, Katchar K, Goldsmith JD, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology. 2008;135:1984-1992.
22. Schmidt JV, Su GH, Reddy JK, et al. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA. 1996;93:6731-6736.
23. Geem D, Medina-Contreras O, Kim W, et al. Isolation and characterization of dendritic cells and macrophages from the mouse intestine. J Vis Exp. 2012;(63):e4040.
24. El-Zaatari M, Chang YM, Zhang M, et al. Tryptophan catabolism restricts IFN-gamma-expressing neutrophils and Clostridium difficile immunopathology. J Immunol. 2014;193:807-816.
25. Ito S, Chen C, Satoh J, et al. Dietary phytochemicals regulate whole-body CYP1A1 expression through an arylhydrocarbon receptor nuclear translocator-dependent system in gut. J Clin Invest. 2007;117:1940-1950.
26. Bjeldanes LF, Kim JY, Grose KR, et al. Aromatic hydrocarbon responsivenessreceptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc Natl Acad Sci USA. 1991;88:9543-9547.
27. Hasegawa M, Kamada N, Jiao Y, et al. Protective role of commensals against Clostridium difficile infection via an IL-1beta-mediated positive-feedback loop. J Immunol. 2012;189:3085-3091.
28. Naik R, Nixon S, Lopes A, et al. A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer. 2006;16:786-790.
29. Bradlow HL, Michnovicz JJ, Halper M, et al. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomarkers Prev. 1994;3:591-595.
30. Minich DM, Bland JS. A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals. Nutr Rev. 2007;65:259-267.
31. Peter Guengerich F, Martin MV, McCormick WA, et al. Aryl hydrocarbon receptor response to indigoids in vitro and in vivo. Arch Biochem Biophys. 2004;423:309-316.
32. Benson JM, Shepherd DM. Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol Sci. 2011;124:327-338.
33. Lahvis GP, Lindell SL, Thomas RS, et al. Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci USA. 2000;97:10442-10447.
34. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28:546-558.
35. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566-569.
36. Alam SN, Yammine H, Moaven O, et al. Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. Ann Surg. 2014;259:715-722.
37. McAleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev. 2014;260:129-144.
38. Bliss DZ, Johnson S, Savik K, et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med. 1998;129:1012-1019.